228 related articles for article (PubMed ID: 10711822)
1. Hypervolumetric hemodilution with HES 100/0.5 10% in patients with peripheral arterial occlusive disease (Fontaine, stage II): an open clinical and pharmacological phase IV study.
Koscielny J; Latza R; Pruss A; Kiesewetter H; Jung F; Meier C; Schimetta W
Clin Hemorheol Microcirc; 2000; 22(1):53-65. PubMed ID: 10711822
[TBL] [Abstract][Full Text] [Related]
2. [Iso- and hypervolemic hemodilution with hydroxyethyl starch (HES 200/.05 10%) in patients with II b peripheral arterial occlusive disease].
Kiesewetter H; Blume J; Jung F; Spitzer S; Gerhards M; Waldhausen P; Wenzel E
Wien Med Wochenschr; 1989 Sep; 139(17):396-401. PubMed ID: 2480029
[TBL] [Abstract][Full Text] [Related]
3. [Hyper- or isovolemic hemodilution in patients with stage II peripheral arterial occlusive disease].
Kiesewetter H; Jung F; Blume J; Spitzer S; Birk A
Acta Med Austriaca; 1991; 18 Suppl 1():23-7. PubMed ID: 1719729
[TBL] [Abstract][Full Text] [Related]
4. [Hypervolemic hemodilution with medium molecular-weight hydroxyethyl starch: effect of duration of administration on viscoelasticity of blood in IIa and IIb peripheral arterial occlusive disease].
Költringer P; Langsteger W; Lind P; Klima G; Pierer G; Reisecker F; Eber O
Acta Med Austriaca; 1991; 18 Suppl 1():45-7. PubMed ID: 1719731
[TBL] [Abstract][Full Text] [Related]
5. [Kinetic effects of 6% hydroxyethyl starch 200.000/0.6-0.66 in hypervolemic hemodilution].
Költringer P; Langsteger W; Lind P; Klima G; Pierer G; Reisecker F; Eber O
Acta Med Austriaca; 1991; 18 Suppl 1():20-2. PubMed ID: 1719728
[TBL] [Abstract][Full Text] [Related]
6. HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics.
Treib J; Haass A; Pindur G; Seyfert UT; Treib W; Grauer MT; Jung F; Wenzel E; Schimrigk K
Thromb Haemost; 1995 Dec; 74(6):1452-6. PubMed ID: 8772219
[TBL] [Abstract][Full Text] [Related]
7. [Hemodilution in patients with multiple morbidity and peripheral arterial occlusive disease].
Kiesewetter H; Blume J; Jung F; Spitzer S; Bach R; Birk A; Schieffer H; Wenzel E
Schweiz Med Wochenschr; 1989 Dec; 119(51):1862-7. PubMed ID: 2481883
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of 2 6% middle-molecular hydroxyethyl starch solutions on elimination kinetics and flow characteristics of blood in volunteers].
Koscielny J; Jung F; Mrowietz C; Pindur G; Förster H; Schimetta W; Kiesewetter H; Wenzel E
Infusionsther Transfusionsmed; 1994 Aug; 21(4):251-9. PubMed ID: 7524833
[TBL] [Abstract][Full Text] [Related]
9. [Hemorheologic, micro- and macrocirculatory effects of an infusion of 500 ml of 6% medium molecular weight hydroxyethyl starch (Haes 200,000/0.5)].
Jung F; Waldhausen P; Mrowietz C; Spitzer S; Kiesewetter H; Wenzel E
Infusionstherapie; 1989 Aug; 16(4):148-54. PubMed ID: 2478482
[TBL] [Abstract][Full Text] [Related]
10. [Effect of hemodilution with 10% hydroxyethyl starch solution (MW 200,000/9.5) on the flow properties of blood, arterial blood gases and conjunctival oxygen partial pressure in patients with cerebral infarct].
Staedt U; Hütt M; Herrmann B; Seufzer U; Leweling H
Infusionstherapie; 1989 Jun; 16(3):107-12. PubMed ID: 2474508
[TBL] [Abstract][Full Text] [Related]
11. Haemodilution with medium molecular weight hydroxyethyl starch in patients with peripheral arterial occlusive disease stage IIb.
Kiesewetter H; Blume J; Jung F; Spitzer S; Wenzel E
J Intern Med; 1990 Feb; 227(2):107-14. PubMed ID: 1688914
[TBL] [Abstract][Full Text] [Related]
12. [Middle-molecular hydroxyethyl starch as a volume substitute. Its rheological effect in peripheral arterial occlusive diseases].
Kiesewetter H; Blume J; Bulling B; Gerhards M; Jung F; Radtke H; Franke RP
Dtsch Med Wochenschr; 1984 Nov; 109(48):1844-7. PubMed ID: 6209081
[TBL] [Abstract][Full Text] [Related]
13. [Isovolemic hemodilution in stage-IIb peripheral arterial occlusive diseases. Prospective randomized double-blind comparison of middle-molecule hydroxyethyl starch and electrolyte solution].
Kiesewetter H; Jung F; Blume J; Gerhards M
Dtsch Med Wochenschr; 1986 Aug; 111(35):1307-12. PubMed ID: 2427301
[TBL] [Abstract][Full Text] [Related]
14. [Hemorheologic, micro- and macrocirculatory effects of hypervolemic hemodilution with middle molecular weight hydroxyethyl starch (Haes 200/0.62; 6 percent)].
Jung F; Waldhausen P; Spitzer S; Mrowietz C; Häuser B; Wenzel E
Infusionstherapie; 1988 Dec; 15(6):265-71. PubMed ID: 2466797
[TBL] [Abstract][Full Text] [Related]
15. [Effect of hemodilution on systemic and capillary hematocrit].
Jung F; Koscielny J; Mrowietz C; Wolf S; Kiesewetter H; Wenzel E
Infusionstherapie; 1990 Oct; 17(5):268-75. PubMed ID: 1705247
[TBL] [Abstract][Full Text] [Related]
16. [Degree of substitution and volume expanding effect of various medium molecular weight hydroxyethyl starch solutions].
Kröll W; Pölz W; Colombo T; Steindorfer P
Wien Klin Wochenschr; 1994; 106(13):416-21. PubMed ID: 7522379
[TBL] [Abstract][Full Text] [Related]
17. [Hemorheologic, micro- and macrocirculatory effects of hypervolemic infusions of middle molecular weight hydroxyethyl starch (10%, 200,000/0.62) in healthy probands].
Scheffler P; Jung F; Mrowietz C; Waldhausen P; Leipnitz G; Häuser B
Infusionsther Klin Ernahr; 1987 Oct; 14(5):233-8. PubMed ID: 2445681
[TBL] [Abstract][Full Text] [Related]
18. [Continuous hemodilution using a low-molecular hydroxyethyl starch solution. Pilot studies in patients with acute cerebral ischemia].
Fuchs M; Henkel P; Becker-Scheid D; Schmitt J
Infusionstherapie; 1990 Aug; 17(4):205-9. PubMed ID: 1698719
[TBL] [Abstract][Full Text] [Related]
19. [Hemorheologic and circulatory effects of hemodilution with medium molecular weight hydroxyethyl starch in two concentrations (HAES 200/0.62 10% and 6%)].
Jung F; Waldhausen P; Spitzer S; Wenzel E
Acta Med Austriaca; 1991; 18 Suppl 1():9-15. PubMed ID: 1719736
[TBL] [Abstract][Full Text] [Related]
20. [Effect of stepwise hypervolemic versus isovolemic hemodilution in patients with intermittent claudication on muscle oxygen pressure during exercise].
Höffkes HG; Saeger-Lorenz K; Ehrly AM
Vasa; 1991; 20(2):109-18. PubMed ID: 1877329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
